Do you want to read an article? Please log in or register.
Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure
BMC Gastroenterol
Heng Z, Zhan L, Zhang Y, Xu K, Song M, Zhao K, Jahan MS, Akter MF, Lu P, Ji Y, Liu Y
doi: 10.1186/s12876-026-05078-9
Inflammatory Bowel Disease
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab
Inflamm Bowel Dis
Lee J, Porth R, Saraga A, Gade A, Deyhim T, Soliman M, Moini SH, Zullow S, Rabinowitz L, Grossberg L, Cheifetz AS, Papamichael K
doi: 10.1093/ibd/izag139
Inflammatory Bowel Disease
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis
Clin Gastroenterol Hepatol
Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, Zingone F, Lago IR, Onali S, Caprioli FA, Chaparro M, Acosta MB, Karmiris K, Degabli NT, Dar L, Pastorelli L, Gutiérrez A, Orlando A, Zabana Y, Saibeni S, Piovani D, Savarino EV, Pugliese D, Magro F, Danese S, Armuzzi A, PODIUM Study Group, Bonovas S, Fanizzi F, Ferraz P, Scaldaferri F, Barberio B, Moraleja I, Favale A, Noviello D, Gisbert JP, Porto-Silva M, Psistakis A, Yanai H, Kopylov U, Di Pietro M, Madero-Velázquez L, Macaluso FS, Orlando R, Gabbiadini R, Buono AD, Loy L, Migliorisi G, Zoratti C
doi: 10.1016/j.cgh.2026.01.017
Inflammatory Bowel Disease
Serious infections in patients with inflammatory bowel disease and corticosteroids: A propensity score-matched study
Clin Gastroenterol Hepatol
Forss A, Axelrad J, Söderling J, Mårild K, SWIBREG study group, Grip O, Hreinsson JP, Halfvarson J, Naucler P, Ludvigsson JF, Olén O
doi: 10.1016/j.cgh.2026.08.019
Inflammatory Bowel Disease
Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease
Inflamm Bowel Dis
Khan N, Sundararajan R, Patel D, Patel M, Bahirwani J, Mahmud N
doi: 10.1093/ibd/izaf218
COMMENTED
Inflammatory Bowel DiseaseFurther Publications
A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Am J Gastroenterol
Vavricka SR, Zeitz J, Madanchi M, Ruiz PA, Biedermann L, Morsy Y, Yilmaz B, Scharl M, Scharl S, Gassmann M, Lutz TA, Kunz A, Bron D, Misselwitz B, MacPherson AJ, Rogler G, Greuter T
doi: 10.14309/ajg.0000000000003888
Inflammatory Bowel Disease
Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations
Adv Ther
Piche SL, Becker MD, Bhat S, Huang LL, Kane SV
doi: 10.1007/s12325-026-03584-6
Inflammatory Bowel Disease
Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)
Inflamm Bowel Dis
Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, Huang TY, Yen HH, Tsai TJ, Lin CP, Chang CH, Tai CM, Tai WC, Yao CC, Chen CC, Pan YB, Le PH
doi: 10.1093/ibd/izag150
Inflammatory Bowel Disease
Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis
BMC Gastroenterol
Gu Y, Zhang X, Gu L, Zou D
doi: 10.1186/s12876-026-04975-3